Clicky

UCB SA(UCBJF)

Description: UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.


Keywords: Medicine Biopharmaceutical Clinical Medicine Monoclonal Antibodies Parkinson's Disease Rheumatoid Arthritis Arthritis Psoriasis Osteoporosis Epilepsy Crohn's Disease Rheumatology Allergies Psoriatic Arthritis Immunosuppressants Systemic Lupus Erythematosus Plaque Psoriasis Seizure Myasthenia Gravis Ankylosing Spondylitis Immune Thrombocytopenia Hidradenitis Suppurativa Treatment Of Osteoporosis Chronic Inflammatory Demyelinating Polyneuropathy Severe Diseases Immunology Diseases Restless Legs Syndrome Certolizumab Pegol Cimzia Keppra Neupro Vimpat Alprazolam Contract Manufacturing Activities Drug Resistant Epilepsy Immune Mediated Necrotizing Myopathy Inflammatory Tnf Mediated Diseases Progressive Supranuclear Palsy Tauopathies Ucb Xyzal Zyrtec Active Epileptic Seizure Therapies And Solutions

Home Page: www.ucb.com

Allée de la Recherche, 60
Brussels, 1070
Belgium
Phone: 32 2 559 99 99


Officers

Name Title
Mr. Jean-Christophe Tellier CEO & Exec. Director
Ms. Sandrine Dufour CFA Exec. VP & CFO
Ms. Kirsten Lund-Jurgensen Exec. VP of Supply & Technology Solutions
Dr. Dhavalkumar D. Patel M.D., Ph.D. Exec. VP & Chief Scientific Officer
Mr. William J. Silbey Exec. VP & Gen. Counsel
Mr. Jean-Luc Fleurial Exec. VP & Chief HR Officer
Prof. Iris Low-Friedrich Exec. VP, Chief Medical Officer and Head of Devel. & Medical Patient Value Practices
Mr. Emmanuel Caeymaex Exec. VP of Immunology Solutions & Head of US
Mr. Charl van Zyl Exec. VP of Neurology Solutions & Head of EU/International
Ms. Caroline Vancoillie Chief Accounting Officer & CFO of Patient Value Functions

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 17.1527
Trailing PE: 17.1547
Price-to-Book MRQ: 1.5169
Price-to-Sales TTM: 2.5008
IPO Date:
Fiscal Year End: December
Full Time Employees: 8600
Back to stocks